Search results for "Gynecologic oncology"

showing 10 items of 20 documents

Pelvic exenteration for recurrent endometrial adenocarcinoma: a retrospective multi-institutional study about 21 patients.

2014

ObjectiveThe aim of our study was to evaluate morbidity, mortality, and long-term survival of patients who underwent pelvic exenteration (PE) with curative intent for recurrence of endometrial adenocarcinoma during a single decade.MethodsWe defined a cohort of 21 patients who met our inclusion criteria, referred to 4 cooperating gynecologic oncology settings in Germany and Italy between 2000 and 2011. Data regarding surgery, histology, and oncologic outcomes were collected and statistically evaluated. Survival was determined from the day of exenteration until the last follow-up or death.ResultsThe median age was 66 years. A total of 42.9% of the patients had major complications, and a compl…

Pelvic Neoplasmmedicine.medical_specialtySurvivalPrognosimedicine.medical_treatmentendometrial adenocarcinomaGynecologic oncologyAdenocarcinomaFollow-Up StudieRetrospective StudiemedicineHumansEndometrial NeoplasmPelvic NeoplasmsSurvival rateAgedNeoplasm StagingPelvic NeoplasmsRetrospective StudiesAged 80 and overPelvic exenteration recurrent endometrial adenocarcinomaPelvic exenterationbusiness.industryMedicine (all)Endometrial cancerGeneral surgeryObstetrics and GynecologyRecurrent endometrial cancerRetrospective cohort studyPerioperativeMiddle Agedmedicine.diseasePrognosisSurgeryEndometrial Neoplasmspelvic exenterationSurvival RateSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyCohortFemaleMorbidityNeoplasm Recurrence LocalbusinessHumanFollow-Up Studies
researchProduct

23 Impact of COVID-19 in gynecologic oncology: a nationwide Italian survey

2020

Objective Several attempts are done in order to control COVID-19 and promote a fair allocation of resources during the outbreak. The Italian society of obstetrics and gynecologist (SIGO), and the Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) are promoting research activities in the field of gynecologic oncology on a national basis, even in the era of COVID-19. Methods The SIGO and MITO group promoted a national survey aiming to evaluate the impact of COVID-19 on clinical activity of gynecologist oncologists and the implementation of containment measures of COVID-19 diffusion. Results Overall, 604 participants completed the questionnaire with a response rat…

Response rate (survey)Laparoscopic surgerymedicine.medical_specialtymedicine.diagnostic_testCoronavirus disease 2019 (COVID-19)business.industrymedicine.medical_treatmentOutbreakGynecologic oncologyTriageFamily medicinePandemicmedicineLaparoscopybusinessOral Poster – LIVE
researchProduct

Role of Cytoreductive surgery in recurrent ovarian cancer

2010

Ovarian cancer is the leading cause of death from gynecologic malignancy in western countries, primarily because over 60% of patients with ovarian cancer will experience disease recurrence. Primary cytoreductive surgery and combination chemotherapy are the cornerstones of the initial treatment for epithelial ovarian cancer. The management of recurrent ovarian cancer is less clear than that of primary disease. The management of recurrent ovarian cancer is largely based on systemic chemotherapy, with surgery being offered only in selected individuals. Despite this, the benefits of surgery has been shown in a meta-analysis by Bristow et al. where the survival is influenced by the completeness …

Secondary cytoreductionOncologymedicine.medical_specialtyendocrine system diseaseshypertermic intraoperative peritoneal chemotherapyGynecologic oncology; HIPEC; Hyperthermic intraoperative peritoneal chemotherapy; Recurrent ovarian cancer; Secondary cytoreductionGinecologic oncology Hipec recurrent ovarian cancer secondary cytoreductionDiseaseGynecologic oncologyHyperthermic intraoperative peritoneal chemotherapyInternal medicinemedicinePharmacology (medical)Cause of deathHIPECbusiness.industrySystemic chemotherapyCombination chemotherapyGeneral Medicinemedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaGynecologic oncologyGinecologic oncology Hipec recurrent ovarian cancer secondary cytoreduction; hypertermic intraoperative peritoneal chemotherapyRecurrent Ovarian CancerRecurrent ovarian cancerbusinessOvarian cancerCytoreductive surgery
researchProduct

Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective…

2015

Objective The International Federation of Gynecology and Obstetrics (FIGO) staging for cervical cancer is based on clinical examination. Previous studies have demonstrated significant upstaging with surgical staging. However, no randomized trial has ever shown a survival benefit when radiation combined with chemoradiation (RCTX) is modified according to surgical staging. The objective of the study was to evaluate the feasibility and outcomes of surgical staging prior to radical RCTX treatment among patients with locally advanced cervical cancer in the setting of a larger, prospective, randomized study (the Uterus-11 study of the German Gynecologic Oncology Group). Study Design Between 2009 …

Uterine Cervical Neoplasmmedicine.medical_treatmentBrachytherapyUterine Cervical NeoplasmsCarcinoma AdenosquamouAntineoplastic AgentPostoperative ComplicationsLaparotomyrandomized triallocally advanced cervical cancerLaparoscopyCervical cancermedicine.diagnostic_testMedicine (all)Lymph NodeObstetrics and GynecologyChemoradiotherapyMiddle Agedlaparoscopic stagingTreatment OutcomeCarcinoma Squamous CellFemaleoperative morbidityHumanAdultmedicine.medical_specialtyPelviBrachytherapyAntineoplastic AgentsGynecologic oncologyAdenocarcinomaPelvisCarcinoma AdenosquamousYoung AdultmedicineHumansExternal beam radiotherapyAgedNeoplasm StagingRadiotherapybusiness.industryPostoperative complicationPerioperativemedicine.diseaseSurgeryFeasibility StudieFeasibility StudiesLymph Node ExcisionLaparoscopyPostoperative ComplicationLymph NodesCisplatinbusinessAmerican journal of obstetrics and gynecology
researchProduct

Beyond Sentinel Lymph Node: Outcomes of Indocyanine Green-Guided Pelvic Lymphadenectomy in Endometrial and Cervical Cancer

2023

Background: The aim of our study was to compare the number of lymph nodes removed during indocyanine green (ICG)-guided laparoscopic/robotic pelvic lymphadenectomy with standard systematic lymphadenectomy in endometrial cancer (EC) and cervical cancer (CC). Methods: This is a multicenter retrospective comparative study (Clinical Trial ID: NCT04246580; updated on 31 January 2023). Women affected by EC and CC who underwent laparoscopic/robotic systematic pelvic lymphadenectomy, with (cases) or without (controls) the use of ICG tracer injection within the uterine cervix, were included in the study. Results: The two groups were homogeneous for age (p = 0.08), Body Mass Index, International Fede…

indocyanine greenRobotic surgery.pelvic lymphadenectomycervical cancerHealth Toxicology and Mutagenesisendometrial cancerrobotic surgeryPublic Health Environmental and Occupational Healthlaparoscopygynecologic oncologySettore MED/40 - Ginecologia E Ostetriciaminimally invasive surgerycervical cancer; endometrial cancer; gynecologic oncology; indocyanine green; laparoscopy; minimally invasive surgery; pelvic lymphadenectomy; robotic surgery
researchProduct

Nationwide Analysis on Surgical Staging Procedures and Systemic Treatment for Patients With Endometrial Cancer in Germany

2012

ObjectiveIn 2009 and 2006, the Arbeitsgemeinschaft Gynäkologische Onkologie evaluated therapeutic approaches for endometrial carcinoma (EC) in Germany.Methods and MaterialsA questionnaire was developed and sent to 775 German gynecologic departments in 2009 (500 in 2006). The results of the questionnaires were compared with each other and with the recommendations of the Arbeitsgemeinschaft Gynäkologische Onkologie’s guideline. Subgroup analyses were performed, dividing the participating centers into small and large centers and into centers with less and more experience with EC.ResultsResponses were available in 33.3% in 2009 and 35.8% in 2006. Comparing 2009 with 2006, it became apparent tha…

medicine.medical_specialtyGynecologic oncologySurgical stagingGynecologic Surgical ProceduresGermanySurveys and QuestionnairesCytologyAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansMulticenter Studies as TopicPelvic lymphadenectomyDiagnostic Techniques Obstetrical and GynecologicalNeoplasm StagingGynecologybusiness.industryData CollectionGeneral surgeryEndometrial cancerObstetrics and GynecologyProfessional PracticeGuidelinemedicine.diseaseHospitalsPeritoneal washingEndometrial NeoplasmsOncologyLymph Node ExcisionFemaleGuideline AdherencebusinessCarcinoma EndometrioidInternational Journal of Gynecologic Cancer
researchProduct

Synchronous Ovarian and Endometrial Cancer—an International Multicenter Case-Control Study

2013

ObjectivesThis study aimed to compare the prognosis of patients with synchronous endometrial and ovarian cancer (SEOC) to matched controls with either endometrial cancer (EC) or ovarian cancer (OC).MethodsA retrospective case-control study including all patients with SEOC who had been treated at 5 European tertiary gynecologic oncology centers between 1996 and 2011 and patients with either EC or OC matched for age, International Federation of Gynecology and Obstetrics (FIGO) stage, histology, year of diagnosis, and Eastern Cooperative Oncology Group performance score.ResultsThe study cohort comprised 77, 132, and 126 patients with SEOC, EC, and OC, respectively. The patient characteristics …

medicine.medical_specialtyMedizinGynecologic oncologyDisease-Free SurvivalCohort StudiesNeoplasms Multiple PrimaryTertiary Care CentersGermanymedicineHumansStage (cooking)Retrospective StudiesOvarian NeoplasmsGynecologybusiness.industryEndometrial cancerCarcinomaCase-control studyObstetrics and GynecologyRetrospective cohort studyMiddle Agedmedicine.diseaseEndometrial NeoplasmsOncologyCase-Control StudiesCohortFemalebusinessOvarian cancerCohort studyInternational Journal of Gynecologic Cancer
researchProduct

382 Molecular classification of endometrial carcinoma substantially changing risk-assessment: Results from a european multicentre initiative

2021

Introduction/Background* Endometrial carcinoma patient care was based on histopathologic examination for many years. However, conventional pathologic features are known to suffer from high inter-observer variability and may be irreproducible in many cases. TCGA-derived molecular classification was shown to provide clinically meaningful data and was recently introduced to ESGO/ESTRO/ESP endometrial carcinoma consensus guidelines. It was the aim of this study to quantify alterations in risk-assessment if molecular classification is added to conventional prognosticators. Methodology Consecutive primary endometrial carcinoma patients diagnosed in 2016 were identified in participating centres. O…

medicine.medical_specialtybusiness.industryGynecologic oncologyDiseasePrecision medicineLower riskmedicine.diseaseMSH6Internal medicineCarcinomaMedicineStage (cooking)businessRisk assessmentEndometrial cancer
researchProduct

Surgery vs. chemotherapy for ovarian cancer recurrence: what is the best treatment option

2020

Nowadays, the best treatment option for ovarian cancer recurrence is often subjective, can vary in the different centers and depend on personal experience. Arbeitsgemeinschaft Gynaekologische Onkologie (AGO)-DESKTOP studies have identified a population of patients who could benefit from secondary surgery. The results of the Gynecologic Oncology Group (GOG)-0213 study were recently published, which showed no advantage in terms of overall survival (OS) in patients with platinum-sensitive recurrent epithelial ovarian undergoing secondary cytoreductive surgery (SCS) compared to chemotherapy alone. Aim of this narrative review is to summarize the best aspects that can make ovarian cancer recurre…

medicine.medical_specialtyeducation.field_of_studyChemotherapyendocrine system diseasesPerformance statusbusiness.industrymedicine.medical_treatmentPopulationTreatment optionsGynecologic oncologymedicine.diseaseSurgery03 medical and health sciences0302 clinical medicineRecurrent Ovarian Cancer030220 oncology & carcinogenesismedicineSurgery030212 general & internal medicineOvarian cancereducationbusinessContraindicationGland Surgery
researchProduct

Minimally Invasive Approaches in Locally Advanced Cervical Cancer Patients Undergoing Radical Surgery After Chemoradiotherapy: A Propensity Score Ana…

2020

Abstract Purpose Chemoradiation (CT/RT) followed by radical surgery (RS) may play a role in locally advanced cervical cancer (LACC) patients with suboptimal response to CT/RT or in low-income countries with limited access to radiotherapy. Our aim is to evaluate oncological and surgical outcomes of minimally invasive radical surgery (MI-RS) compared with open radical surgery (O-RS). Patients and Methods Data for stage IB2–IVA cervical cancer patients managed by CT/RT and RS were retrospectively analyzed. Results Beginning with 686 patients, propensity score matching resulted in 462 cases (231 per group), balanced for FIGO stage, lymph node status, histotype, tumor grade, and clinical respons…

medicine.medical_specialtymedicine.medical_treatmentConcomitant Chemoradiation Neoadjuvant Chemotherapy Phase III Hysterectomy Radiation Therapy WomenUterine Cervical NeoplasmsHysterectomyDisease-Free Survival03 medical and health sciences0302 clinical medicinePhase IIIlocally advanced cervical cancer (LACC)locally advanced cervical cancerHumansMedicineWomenChemoradiotherapy; Disease-Free Survival; Female; Humans; Hysterectomy; Neoadjuvant Therapy; Neoplasm Recurrence Local; Neoplasm Staging; Propensity Score; Retrospective Studies; Uterine Cervical Neoplasms030212 general & internal medicineStage (cooking)Radical surgeryPropensity ScoreNeoadjuvant therapyNeoplasm StagingRetrospective StudiesCervical cancerHysterectomyRadiationbusiness.industrylocally advanced cervical cancer surgeryNeoadjuvant ChemotherapyRetrospective cohort studyChemoradiotherapyGynecologic Oncologymedicine.diseaseNeoadjuvant TherapySurgeryRadiation therapySettore MED/40 - GINECOLOGIA E OSTETRICIANeoplasm RecurrenceLocalOncology030220 oncology & carcinogenesisConcomitant ChemoradiationFemaleSurgeryTherapyNeoplasm Recurrence LocalbusinessChemoradiotherapy
researchProduct